The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Anand Sharma
Consulting or Advisory Role - BMS; MSD Oncology
Speakers' Bureau - BMS GmbH & Co. KG; Eisai/MSD; EUSA Pharma; ipsen; Janssen Oncology; Merck Serono; MSD Oncology; Pfizer/EMD Serono
Travel, Accommodations, Expenses - EUSA Pharma; EUSA Pharma; Ipsen; MSD
 
Balaji Venugopal
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer/EMD Serono
Speakers' Bureau - Eisai; Ipsen; Janssen Oncology; MSD Oncology; Pfizer
Research Funding - Calithera Biosciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - EUSA Pharma; Ipsen
 
Jens Bedke
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck KGaA; MSD Oncology; Pfizer; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Seagen (Inst)
 
Pascale Dutailly
Employment - Ipsen
 
Bryan Qvick
Employment - Ipsen
 
Lidia Martin-Couce
Employment - Ipsen
Stock and Other Ownership Interests - Biogen; Ipsen
 
Valérie Perrot
Employment - Ipsen
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; AstraZeneca; Bristol-Myers Squibb; ClinSol; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Debiopharm Group; Eisai; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Onkowissen; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Ipsen (Inst); MSD Oncology (Inst); Novartis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Pfizer